{"publication_id":"bb8686c3-28f9-4609-95f1-70d7581bf992","screening":{"identified":36,"screened":36,"excluded":0,"included":36,"included_or_retained":36,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"36 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["Evidence-honesty note: 33/36 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This paper synthesizes evidence on pcsk9 inhibitors effects across 36 included source papers and 1548 high-confidence extracted claims. The evidence profile contains 3 direct clinical sources, 33 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base. Positive study-level signals are summarized in the cardiometabolic and longevity outcome classes; null signals are summarized in the safety and comorbidity, mortality and survival, and muscle function outcome classes; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the contextual adjacent evidence, safety, and skeletal, fracture, and bone outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.","Positive study-level signals are summarized in the cardiometabolic and longevity outcome classes; null signals are summarized in the safety and comorbidity, mortality and survival, and muscle function outcome classes; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the contextual adjacent evidence, safety, and skeletal, fracture, and bone outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.","The conclusion is that pcsk9 inhibitors effects remains a bounded evidence case: the retained direct, adjacent, and context evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim.","The corpus contains 3 direct clinical sources, 33 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.","Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.","The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.","The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.","The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.","Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.","Findings Map accounting note: each outcome-class n, direction count, directness count, and source roster is computed from the same source-level rows listed in the detailed table. Receipt-level direction is not a statement that the source abstracts lack directional statistics; it is the conservative coded polarity used for synthesis accounting. Outcome-class roster: Cardiometabolic n=14 (direction: negative=1; null=4; positive=6; unclear=3; directness: direct=1; indirect=3; review=10; sources: Ariyanti 2026 [bundle:29]; Cao 2025 [bundle:6]; Du 2019 [bundle:33]; Gong 2025 [bundle:26]; Hollstein 2021 [bundle:2]; Imran 2023 [bundle:3]; Khan 2018 [bundle:34]; Raone 2025 [bundle:9]; Ray 2025 [bundle:27]; Rehues 2023 [bundle:5]; Scicali 2021 [bundle:4]; Turgeon 2018 [bundle:35]; Wang 2022a [bundle:13]; Wang 2022b [bundle:23]); Contextual Adjacent Evidence n=9 (direction: null=1; positive=3; unclear=5; directness: direct=1; indirect=7; review=1; sources: Akhtar 2025 [bundle:24]; Barbati 2024 [bundle:21]; Bosco 2025 [bundle:18]; Chen 2026 [bundle:15]; Hosseini 2024 [bundle:1]; Jing 2025 [bundle:8]; Kuhl 2019 [bundle:32]; Seijas-Amigo 2023 [bundle:22]; Yu 2026 [bundle:25]); Safety and Comorbidity n=6 (direction: mixed=1; null=5; directness: indirect=1; review=5; sources: Jiang 2025 [bundle:16]; Liu 2024 [bundle:7]; Masson 2026 [bundle:14]; Song 2024 [bundle:10]; Theodorou 2025 [bundle:28]; Xiao 2024 [bundle:11]); Safety n=3 (direction: mixed=1; null=1; positive=1; directness: direct=1; review=2; sources: Choi 2023 [bundle:12]; Karatasakis 2017 [bundle:31]; Schmidt 2017 [bundle:36]); Longevity n=1 (direction: positive=1; directness: review=1; sources: Hu 2025 [bundle:30]); Mortality and Survival n=1 (direction: null=1; directness: review=1; sources: Zhang 2025 [bundle:20]); Muscle Function n=1 (direction: null=1; directness: review=1; sources: Li 2024 [bundle:17]); Skeletal, Fracture, and Bone n=1 (direction: mixed=1; directness: review=1; sources: Chen 2024 [bundle:19]).","Tension-accounting note: disagreement counts are claim-level. Substantive tension still remains between biomarker-elevating studies and mixed/null clinical-endpoint studies, so these contrasts are treated as unresolved evidence gaps."]}